Three-year data from a comparative study with recombinant human growth hormone in the treatment of short stature in young children with intrauterine growth retardation.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

At birth, their mean weight standard deviation score (SDS) was -2.5 and their mean length SDS -3.5.

At baseline, the patients were prepubertal, non-GH deficient, with no known dysmorphic features.

Who Took Part

According to the abstract, 3 children were involved.

PubMed indexes the participants as young children, children and teenagers, both men and women.

The patients were enrolled in an open, multicentre trial and were randomly allocated to either the treated group (Group 1) or the control group (Group 2).

How the Study Was Run

The researchers set it up as a randomized and multicenter study.

The children were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

More than one site took part, so the children came from several places.

What Was Measured

At birth, their mean weight standard deviation score (SDS) was -2.5 and their mean length SDS -3.5.

Topics PubMed links to this paper include Body Height, Body Mass Index, Fetal Growth Retardation, Human Growth Hormone and Puberty.

What This Means in Plain Language

The paper is a randomized and multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 3 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 1998 (Acta paediatrica (Oslo, Norway : 1992)), a journal based in Norway.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.